---
schema_version: "secwatch.filing_event.v1"
accession: "0001743881-25-000010"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:41:30.217957+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q3 2025: $120.7M revenue, Attruby launch accelerating; positive Phase 3 data for BBP-418 and encaleret

## Summary
- Total revenue $120.7M (Q3 2024: $2.7M), driven by $108.1M Attruby net product revenue.
- Net loss $182.7M ($0.95/sh) vs $162.0M ($0.86/sh) in prior year; cash $645.9M.
- Attruby: 5,259 prescriptions written by 1,355 prescribers since Nov 2024 approval.
- BBP-418 Phase 3 met endpoints: glycosylated αDG increased 1.8x (p<0.0001); NDA filing planned 1H 2026.
- Encaleret Phase 3 met primary endpoint: 76% achieved target calcium vs 4% on conventional (p<0.0001); NDA in 1H 2026.

## SEC filing metadata
- accession: 0001743881-25-000010
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/0001743881-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001743881-25-000010
- JSON: https://secwatch.observer/filing/0001743881-25-000010.json
- Plain text: https://secwatch.observer/filing/0001743881-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.